The $100 Billion Frontier: Untapped Potential in Animal Health Innovation
The global animal health market is a staggering $60 billion industry, projected to reach $100 billion by 2030. This phenomenal growth reflects a confluence of factors: rising pet ownership (especially companion animals), increasing protein demand, reducing gaseous emissions, and the ever-present threat of zoonotic diseases.
Advancing mAb manufacturing with customer-centric solutions
Monoclonal antibodies (mAbs) have become a cornerstone in modern therapeutics, offering targeted treatment options across various diseases, including cancer, autoimmune disorders, and infectious diseases.
Selecting the right preclinical species for screening oral dosage form for PK studies
Learn how Syngene helped a pharma client optimize extended-release drug development by identifying the right animal species as a preclinical model. This decision enhanced PK study accuracy, reduced development time, and supported regulatory success for a once-daily epilepsy treatment.
Accelerating development of a unique molecule to treat lung cancer
Learn how Syngene collaborated with a pharma company to develop the drug substance and drug product for a unique molecule to treat locally advanced lung cancer, including optimizing the process to enable commercial manufacturing of the API.
Overcoming analytical challenges with chemical derivatization in LC-MS/MS
Learn about the challenges in chemical derivatization and utilizing LC-MS/MS to detect and quantify trace compounds in complex molecules for supporting bioanalytical studies.
Direct scale up from clone to 2K GMP batches
Learn how Syngene scientists scaled up a clone directly from lab scale to clinical scale and enabled clinical batch manufacturing of the product with an improved titer of >5g/L.
Comprehensive preclinical evaluation of bile acid modulators for paediatric liver disease
Learn how Syngene executed complex preclinical studies, consolidating data across pharmacokinetics, biomarker modulation, and gene expression analysis, and provided comprehensive insights for the client’s development decision on bile acid modulators for paediatric liver disease.
Enabling high product quality, and yield through process optimization for biologics
Learn how Syngene’s expertise in process optimization enabled a biopharma company to achieve high product quality and yield for its PPQ batches, including enabling appropriate scale-up to commercial.
Long acting injectables: Accelerating the path to patient wellbeing
Learn about the various challenges in developing LAIs and the technologies and techniques being used by Syngene to help clients use this transformative drug delivery system to treat chronic diseases.
Developing a green synthesis process for a growth promoter drug for animals
Learn how Syngene developed a green synthesis process for a growth promoter drug for an animal health company that reduced the cE factor and PMI value by 80% while achieving high yield and cost-efficiency.
